{
    "clinical_study": {
        "@rank": "127911", 
        "acronym": "CITRIS-ALI", 
        "arm_group": [
            {
                "arm_group_label": "Ascorbic Acid", 
                "arm_group_type": "Active Comparator", 
                "description": "200mg/kg/day divided over 4 doses.  Administered every 6 hours for 96 hours"
            }, 
            {
                "arm_group_label": "5% Dextrose in Water", 
                "arm_group_type": "Placebo Comparator", 
                "description": "50ml every 6 hours for 96 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ\n      failure as measured by Sequential Organ Failure Assessment (SOFA) score,\n\n      Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by\n      the oxygenation index and the VE40\n\n      Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive\n      Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar\n      epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a\n      fibrinolytic state (Tissue Factor Pathway Inhibitor)."
        }, 
        "brief_title": "Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Lung Injury", 
            "Sepsis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Sepsis", 
                "Toxemia", 
                "Acute Lung Injury", 
                "Respiratory Distress Syndrome, Adult", 
                "Lung Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria for\n        Systemic Inflammatory Response (SIRS) due to infection, and be accompanied by at least 1\n        criterion for sepsis-induced organ dysfunction, and meet all 5 criteria for Acute\n        Respiratory Distress Syndrome (ARDS).\n\n          1. Suspected or proven infection: (e.g., thorax, urinary tract, abdomen, skin, sinuses,\n             central venous catheters, and central nervous system, see Appendix A).\n\n          2. The presence of a systemic inflammatory response: Defined as: fever:  >38\u00baC (any\n             route) or hypothermia: <36\u00baC (core temp only), tachycardia: heart rate > 90 beats/min\n             or receiving medications that slow heart rate or paced rhythm, leukocytosis:  >12,000\n             WBC/\u00b5L or leukopenia:  <4,000 WBC/\u00b5L or >10% band forms.  Respiratory rate > 20\n             breaths per minute or PaCO2 < 32 or  invasive mechanical ventilation.\n\n          3. The presence of sepsis-induced organ dysfunction: (any of the following thought to be\n             due to infection)\n\n               -  Sepsis-induced hypotension (systolic blood pressure (SBP) < 90 mm Hg or an SBP\n                  decrease > 40 mm Hg unexplained by other causes or use of vasopressors for blood\n                  pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine,\n                  vasopressin)\n\n               -  Arterial hypoxemia (PaO2/FiO2 < 300) or supplemental O2 > 6LPM.\n\n               -  Lactate > upper limits of normal laboratory results\n\n               -  Urine output < 0.5 ml/kg/hour for > two hours despite adequate fluid\n                  resuscitation\n\n               -  Platelet count < 100,000 per mcL\n\n               -  Coagulopathy (INR > 1.5)\n\n               -  Bilirubin > 2 mg/dL\n\n               -  Glasgow Coma Scale < 11 or a positive CAM ICU score\n\n          4. ARDS characterized by all the following criteria\n\n               -  Lung injury of acute onset, within 1 week of an apparent clinical insult and\n                  with progression of respiratory symptoms\n\n               -  Bilateral opacities on chest imaging not explained by other pulmonary pathology\n                  (e.g. pleural effusions, lung collapse, or nodules)\n\n               -  Respiratory failure not explained by heart failure or volume overload\n\n               -  Decreased arterial PaO2/FiO2 ratio \u2264 300 mm Hg\n\n               -  Minimum PEEP of 5 cmH2O\n\n        Exclusion Criteria:\n\n          1. Known allergy to Vitamin C\n\n          2. inability to obtain consent;\n\n          3. age < 18 years;\n\n          4. more than 7 days since starting mechanical ventilation;\n\n          5. more than 48 hrs since meeting ARDS criteria;\n\n          6. patient or surrogate or physician not committed to full support (not excluded if\n             patient would receive all supportive care except for cardiac resuscitation);\n\n          7. pregnancy or breast feeding,\n\n          8. moribund patient not expected to survive 24 hours;\n\n          9. home mechanical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP\n             used only for sleep-disordered breathing;\n\n         10. home O2, except for with CPAP/BIPAP\n\n         11. BMI > 40\n\n         12. diffuse alveolar hemorrhage (vasculitis);\n\n         13. interstitial lung disease requiring continuous home oxygen therapy;\n\n         14. Active kidney stone\n\n         15. primary care givers unwilling/unable to use ARDSnet 6 ml/kg ventilation protocol;\n\n         16. Non English speaking;\n\n         17. Ward of the state (inmate, other)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106975", 
            "org_study_id": "HM20000917", 
            "secondary_id": "1UM1HL116885-01"
        }, 
        "intervention": {
            "arm_group_label": "Ascorbic Acid", 
            "intervention_name": "Ascorbic Acid", 
            "intervention_type": "Drug", 
            "other_name": "Vitamin C"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ascorbic Acid", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "greg.martin@emory.edu", 
                    "last_name": "Greg Martin, MD, MSc", 
                    "phone": "404-616-0148"
                }, 
                "contact_backup": {
                    "email": "jsevran@emory.edu", 
                    "last_name": "Jonathan Sevransky, MD, MHS", 
                    "phone": "404-778-0599"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University and Grady Memorial Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Greg Martin, MD, MSc", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jonathan Sevransky, MD, MHS", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hited@ccf.org", 
                    "last_name": "Duncan Hite, MD", 
                    "phone": "216-445-3098"
                }, 
                "contact_backup": {
                    "email": "ferrarm1@ccf.org", 
                    "last_name": "Michelle Ferrari, RN", 
                    "phone": "216-445-1939"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "The Cleveland Clinic"
                }, 
                "investigator": {
                    "last_name": "Duncan Hite, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jonathon.truwit@froedtert.com", 
                    "last_name": "Jonathon Truwit, MD"
                }, 
                "contact_backup": {
                    "email": "jgraf@mcw.edu", 
                    "last_name": "Jeanette Graf", 
                    "phone": "414-955-6987"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Froedtert and The Medical College of Wisconsin"
                }, 
                "investigator": {
                    "last_name": "Jonathon Truwit, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury", 
        "overall_contact": {
            "email": "dewildect@vcu.edu", 
            "last_name": "Christine DeWilde, RN", 
            "phone": "804-628-5710"
        }, 
        "overall_official": {
            "affiliation": "Virginia Commonwealth University", 
            "last_name": "Alpha B. Fowler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in SOFA score at 96 hours as compared to baseline when compared to placebo", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }, 
            {
                "measure": "C-Reactive Protein and Thrombomodulin at study hours 0, 48, 96, 168 when compared to placebo", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106975"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Oxygenation Index (FiO2 x Mean Airway Pressure/PaO2) at study hour 0, 48, 96, 168 if still intubated in ascorbate infused patient compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "VE-40 (Vent RR x TV/Weight) x (PaCO2/40) at study hour 0, 48, 96, 168 if still intubated, in ascorbate infused patient compared to placebo", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA scores at hours 48, 96, 168", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "Ascorbate level at hour 0, 48, 96, 168", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "Ventilator Free Days to day 28", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }, 
            {
                "measure": "ICU-free days at day 28", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }, 
            {
                "measure": "All cause mortality to day 28", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }, 
            {
                "measure": "Hospital-free days at day 60", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 60"
            }, 
            {
                "measure": "Procalcitonin at study hour 0, 48, 96, 168", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "Receptor for Advanced Glycation Endpoints at study hour 0, 48, 96, 168", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "Tissue factor pathway inhibitor at study hour 0, 48, 96, 168", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA Score Component at hours 48,96, 168: PaO2/FiO2", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA Score Components at hours 48,96, 168: SpO2/FiO2", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA Score Components at hours 48,96, 168: Platelets", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA Score Components at hours 48,96, 168: Total Bilirubin", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA Score Components at hours 48,96, 168: Vasopressor status", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA Score Components at hours 48,96, 168: GCS", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }, 
            {
                "measure": "SOFA Score Components at hours 48,96, 168: Creatinine or Urine Output", 
                "safety_issue": "No", 
                "time_frame": "Up to hour 168"
            }
        ], 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}